Shots:

• Novartis recalls three lots of Promacta oral suspension to the consumer level due to the presence of peanut floor contamination occurred at third-party manufacturing facility and is conducted within the knowledge of the US FDA
• The voluntary recall is done for the lot numbers 8H57901589- 9H57900189 & 9H57900289 with no reported adverse event till date. The Promacta 12.5 mg- 25 mg- 50 mg- 75 mg tablets have no impact of the recall
• Promacta (eltrombopag- 12.5 mg-) is a TPO receptor agonist and is indicated for the treatment of chronic immune thrombocytopenia- severe aplastic anemia with no prior immunosuppressive therapy in adults & pediatric patients- also indicated for hepatitis C-associated thrombocytopenia in adults only

  Ref: Novartis | Image: Jekseng